Apologies for the radio silence over the past 18 months. My work life took an interesting turn and I’ve been swamped ever since setting up both a new venture capital firm and a new TechBio startup. I’m back blogging now, and from a different perspective – no longer just a retained adviser, interim CBO or board member for startups, but also a startup CEO and venture investor.
Continue reading “New chapter in my career”Announcing My New Book for Startups
At long last, I have now started serious work on my new book for startups: The Bioscience Startup Journey. Two chapters are already written. And I’m now recruiting beta readers who’ll help me write the book in an agile development way.
Continue reading “Announcing My New Book for Startups”Bioscience and Healthcare Megatrends that Startups Cannot Ignore
Does your startup ride a megatrend? When evaluating a bioscience startup, my first filter is often whether that aspiring business will exploit one of the megatrends sweeping through the bioscience and healthcare sector.
Continue reading “Bioscience and Healthcare Megatrends that Startups Cannot Ignore”Two Common Business Model Misconceptions
This blog post highlights two common misconceptions that bioscience startups often have with respect to their new venture’s business models. These misconceptions can lead to poor decisions that result, at best, in resource-wasting delays before a self-sustaining enterprise is established, and at worst, in their venture’s premature demise.
Continue reading “Two Common Business Model Misconceptions”Business Models for a Young Biotech
What’s my business model? Who do I partner with? How do I scale up? These are typical strategic questions a young biotech will regularly face as it evolves from its initial Seed stage through its Series A, B and C funding rounds.
Continue reading “Business Models for a Young Biotech”3 Drug Development Principles for Smart SMEs
I was inspired to post this article after someone said to me, “The drug development skills learnt in big pharma translate naturally to the biotech world … you just have a smaller budget”. While the technical skills are essentially the same, I feel strongly that the context and mindset in which they are applied are fundamentally different. This article highlights three ways in which “smart” small/medium-sized enterprises (SMEs) conduct drug development.
Continue reading “3 Drug Development Principles for Smart SMEs”Should your Biotech be Virtual?
Many new biotechs start off as virtual companies. But at each stage of development, you always end up asking whether you should stay virtual or build your own in-house wet labs. What are the pros and cons of being virtual? And is there a more pragmatic “semi-virtual” approach?
Continue reading “Should your Biotech be Virtual?”Is Big Always Best?
Many research-stage biotechs and other small to medium-sized enterprises (SMEs) prioritize partnerships with Big Partners or in Big Disease Indications without sufficient consideration of other options. But SMEs need to consider other factors when deciding who to partner their assets with and how. As do large pharmas partnering with SMEs
Continue reading “Is Big Always Best?”Lessons from Leicester City’s success for Bioscience SMEs
As the 2015–16 English Premier League football season ends, I reflect on the lessons that smaller/medium sized enterprises (SMEs) can learn from Leicester City’s unlikely victory. In addition, to the usual lessons on how an underdog can triumph over much bigger competitors, I explore three other important lessons that are less obvious.
Continue reading “Lessons from Leicester City’s success for Bioscience SMEs”Conference Impressions from Strategic Alliance Management for Pharma 2016
Earlier this week, I spent three stimulating days at the 6th annual Strategic Alliance Management for Pharma conference in Barcelona from 18th to 20th April 2016. In this blog post, I highlight those sessions and insights that I personally found most interesting and valuable.
Continue reading “Conference Impressions from Strategic Alliance Management for Pharma 2016”